What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report the execution of an employment agreement between Pfizer Inc. and its Chief Executive Officer, Dr. Henry A. McKinnell, effective January 1, 2001. This agreement details the terms and conditions of his employment.

What is the duration of Dr. McKinnell's employment agreement?

The employment period as outlined in the agreement commences on January 1, 2001, and is set to conclude on February 29, 2008. The agreement also states that it may be extended by mutual agreement of both Pfizer Inc. and Dr. McKinnell.

What are the key compensation components for Dr. McKinnell under this agreement?

Dr. McKinnell's compensation includes an Annual Base Salary, which was initially set at $1,350,000 per annum and can be increased by the Board or its committees. He is also eligible for an annual Incentive Bonus targeted at 100% of his base salary, based on financial and strategic performance. Furthermore, he is eligible to participate in all company plans appropriate to his position, including stock option and other equity-based award programs.

What happens to Dr. McKinnell's equity awards if his employment is terminated without cause?

In the event of termination without cause (or by Dr. McKinnell for good reason), all unvested stock options and other unvested equity-based awards held by Dr. McKinnell will vest immediately on the Date of Termination. These vested options will remain exercisable through their original expiration dates. Additionally, he is entitled to a severance payment calculated based on his base salary and incentive bonus, multiplied by the remaining term of the employment period or a two-year multiple, whichever is greater.

PFE 8-K SEC Disclosure

Summary

Pfizer Inc. (PFE) filed an 8-K on February 2, 2001, to report the execution of an employment agreement with its Chief Executive Officer, Dr. Henry A. McKinnell, effective January 1, 2001. The agreement outlines the terms of Dr. McKinnell's employment as CEO, including his position, responsibilities, and compensation structure. The agreement establishes an employment period from January 1, 2001, to February 29, 2008, with provisions for extension. It details Dr. McKinnell's base salary, eligibility for incentive bonuses, and participation in company plans, including stock options and equity awards. The filing also specifies terms for termination of employment, including provisions for death, disability, retirement, termination for cause, termination without cause, and resignation for good reason. These provisions cover continued compensation, vesting of equity awards, and health benefits.

Key Highlights

1Pfizer Inc. formalized the employment agreement for its CEO, Dr. Henry A. McKinnell, effective January 1, 2001.
2The employment period is set from January 1, 2001, to February 29, 2008, with potential for mutual extension.
3Dr. McKinnell will serve as Chief Executive Officer and is slated for the Chairman of the Board position from April 30, 2001.
4Compensation includes a base salary (initially $1,350,000 per annum), incentive bonuses, and participation in company stock option and equity award programs.
5The agreement details severance packages and benefits upon termination without cause or for good reason, including accelerated vesting of equity awards and continued compensation.
6Provisions for termination due to death, disability, or retirement are outlined, including accelerated vesting of equity and continued health benefits.
7The agreement includes restrictive covenants such as confidentiality, a 12-month non-competition period post-termination, and a 2-year non-solicitation period for employees.

PFIZER INC 8-K Report (Feb 2, 2001)

Summary

Key Highlights

Frequently Asked Questions